vidaza 100 mg/1 bočica prašak za suspenziju za injekciju
amicus pharma d.o.o. - azacitidin - prašak za suspenziju za injekciju - 100 mg/1 bočica - 1 bočica sa praškom za suspenziju za injekciju sadrži: 100 mg azacitidina (nakon rekonstitucije svaki ml suspenzije sadrži 25 mg azacitidina)
azacitidine mylan
mylan ireland limited - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.
azacitidin stada 25 mg/ml prašak za suspenziju za injekciju
stada d.o.o., hercegovačka 14, zagreb, hrvatska - azacitidin - prašak za suspenziju za injekciju - 25 mg/ml - urbroj: svaka bočica sadrži 100 mg azacitidina, nakon rekonstitucije svaki ml suspenzije sadrži 25 mg azacitidina
onureg
bristol-myers squibb pharma eeig - azacitidin - leukemija, mieloidna, akutna - antineoplastična sredstva - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).
vidaculem 25 mg/ml prašak za suspenziju za injekciju
onkogen kft., becsi ut 77-79, budimpešta, mađarska - azacitidin - prašak za suspenziju za injekciju - urbroj: svaka bočica sadrži 100 mg azacitidina. nakon rekonstitucije s 4 ml vode za injekcije, svaki ml suspenzije sadrži 25 mg azacitidina.
azacitidin pharmascience 25 mg/ml prašak za suspenziju za injekciju
pharmascience international limited, lampousas, 1, nicosia, cipar - azacitidin - prašak za suspenziju za injekciju - urbroj: jedna bočica s praškom sadrži 100 mg ili 150 mg azacitidina. nakon rekonstitucije 1 ml suspenzije sadrži 25 mg azacitidina.
etraga 25 mg/ml prašak za suspenziju za injekciju
stada d.o.o., hercegovačka 14, zagreb, hrvatska - azacitidin - prašak za suspenziju za injekciju - urbroj: svaka bočica s praškom sadrži 100 mg ili 150 mg azacitidina nakon rekonstitucije jedan ml suspenzije sadrži 25 mg azacitidina
azacitidin stada 100 mg/1 bočica prašak za suspenziju za injekciju
hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - azacitidin - prašak za suspenziju za injekciju - 100 mg/1 bočica - 1 bočica sa praškom za suspenziju za injekciju sadrži: 100 mg azacitidina (nakon rekonstitucije svaki ml suspenzije sadrži 25 mg azacitidina)
vidaza
bristol-myers squibb pharma eeig - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.
azacitidine celgene
celgene europe bv - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.